Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012474 | 0.82 | JAK2 (0.62) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL803527 | 0.79 | JAK2 (0.74) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL3604523 | 0.78 | YTHDC1 (0.36) | MEN1KMT2AKDM4E | |
| SCHEMBL29243776 | 0.78 | JAK2 (0.66) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL29243644 | 0.78 | JAK2 (0.66) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL4309350 | 0.78 | MEN1 (0.67) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL16097143 | 0.78 | KMT2A (0.62) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL618193 | 0.77 | JAK2 (0.59) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL4239118 | 0.77 | GPR119 (0.56) | JAK2JAK1GPR119STSMEN1 | |
| SCHEMBL389660 | 0.77 | GPR119 (0.43) | JAK2JAK1GPR119STSGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | JAK2 2034/4885JAK1 3701/4885GPR119 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.